← Leaderboards
Jeffery E Joll
Vanderbilt University
$95,948
Attributed
$95,948
Total exposure
1
Grants
1
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $46K · FY2020–22$50K$37.5K$25K$12.5K$0
'20
'21
'22
Funding mix
By agency
NIH$95,948 · 1
By mechanism
F31$95,948 · 1
Top collaborators
No co-investigators on record.
Most similar at Vanderbilt University
Same institution · by research overlap
- Nancy Joan Brown$32,445,188
- William D Merryman$11,751,914
- Stephen N. Davis$16,024,395
- Jessica K Devin$712,930
- Matthew Ryan Bersi$845,981
Others in their field
Other Emerging Leaders on “Ablation”
- James Jeffrey Sahn · 4e Therapeutics Inc.$7,064,669
- Kenneth B. Bader · University Of Chicago$6,109,156
- John R Lukens · University Of Virginia$5,842,869
- Juliette Elizabeth McGregor · University Of Rochester$5,567,728
- Jie Shen · Washington University$5,388,462
- Ashley E Webb · Brown University$5,147,077
Research focus
AblationAdoptionAdverse EffectsAcuteAnalogAntibodiesAortic AneurysmAortic ValveAgingAortic Valve StenosisAreaAtherosclerosisAtomic Force MicroscopyBlood CirculationBlood PumpBlood VesselsCalcificationCardiovascular DiseasesAortic Valve DisorderCardiovascular HealthCardiovascular SystemCell LineCellsCessation Of Life
Grant awards (3)
Investigating the Role of Sclerostin in Calcific Aortic Valve Disease$4,392
F31 · FY2022 · HL · contact PI
Investigating the Role of Sclerostin in Calcific Aortic Valve Disease$46,036
F31 · FY2021 · HL · contact PI
Investigating the Role of Sclerostin in Calcific Aortic Valve Disease$45,520
F31 · FY2020 · HL · contact PI